Iterum Therapeutics Beheer

Hoe is Corey Fishman's beloning veranderd ten opzichte van Iterum Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$31m
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$36m
Dec 31 2023	US$2m	US$612k	-US$38m
Sep 30 2023	n/a	n/a	-US$31m
Jun 30 2023	n/a	n/a	-US$56m
Mar 31 2023	n/a	n/a	-US$51m
Dec 31 2022	US$1m	US$589k	-US$44m
Sep 30 2022	n/a	n/a	-US$44m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	n/a	n/a	US$4m
Dec 31 2021	US$11m	US$573k	-US$92m
Sep 30 2021	n/a	n/a	-US$99m
Jun 30 2021	n/a	n/a	-US$115m
Mar 31 2021	n/a	n/a	-US$135m
Dec 31 2020	US$2m	US$561k	-US$52m
Sep 30 2020	n/a	n/a	-US$64m
Jun 30 2020	n/a	n/a	-US$84m
Mar 31 2020	n/a	n/a	-US$99m
Dec 31 2019	US$1m	US$551k	-US$103m
Sep 30 2019	n/a	n/a	-US$104m
Jun 30 2019	n/a	n/a	-US$97m
Mar 31 2019	n/a	n/a	-US$85m
Dec 31 2018	US$2m	US$495k	-US$77m
Sep 30 2018	n/a	n/a	-US$62m
Jun 30 2018	n/a	n/a	-US$45m
Mar 31 2018	n/a	n/a	-US$36m
Dec 31 2017	US$755k	US$420k	-US$29m

Compensatie versus markt: De totale vergoeding ($USD 1.52M ) Corey } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 646.00K ).

Compensatie versus inkomsten: De vergoeding van Corey is gestegen terwijl het bedrijf verliesgevend is.

CEO

Corey Fishman (59 yo)

9yrs

Tenure

US$1,518,811

Compensatie

Mr. Corey N. Fishman serves as Independent Director at BioSpecifics Technologies Corp. since April 9, 2020. Mr. Fishman has been President, Chief Executive Officer and Director at Iterum Therapeutics plc (...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Corey Fishman	President	9yrs	US$1.52m	0.50% $ 281.0k
Judith Matthews	Chief Financial Officer	9yrs	US$827.77k	0.030% $ 16.7k
Michael Dunne	Strategic Advisor & Director	3.9yrs	US$115.00k	0.80% $ 451.0k
Tom Loughman	Senior Vice President of Technical Operations	3.8yrs	geen gegevens	geen gegevens
Louise Barrett	Senior Vice President of Legal Affairs & Secretary	3.8yrs	geen gegevens	geen gegevens
Steven Aronin	Senior VP & Head of Clinical Development	no data	geen gegevens	geen gegevens

3.9yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ITRM wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Corey Fishman	President	9yrs	US$1.52m	0.50% $ 281.0k
Michael Dunne	Strategic Advisor & Director	3.9yrs	US$115.00k	0.80% $ 451.0k
Ronald Hunt	Independent Chairman of the Board	9yrs	US$88.75k	0.052% $ 29.4k
Beth Hecht	Independent Director	3.7yrs	US$68.50k	0.068% $ 38.6k
David Kelly	Independent Director	8.3yrs	US$74.00k	0.0090% $ 5.1k

8.3yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ITRM wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.3 jaar).

Iterum Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Iterum Therapeutics plc Announces Executive Changes

Iterum Therapeutics plc, Annual General Meeting, Jun 19, 2024

Insufficient new directors

Iterum Therapeutics plc Announces the Resignation of Mark Chin as Director, Effective December 31, 2023

Iterum Therapeutics plc, Annual General Meeting, May 03, 2023

Iterum Therapeutics plc, Annual General Meeting, Jun 15, 2022

Recent updates

Iterum Therapeutics Regains Full Nasdaq Compliance with Listing Rule 5550(b)

Iterum Therapeutics plc to Report Q3, 2024 Results on Nov 14, 2024

Iterum Therapeutics plc Receives U.S. FDA Approval of ORLYNVAH (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics Receives Formal Notice from Nasdaq Panel to Consider its Appeal at an Oral Hearing on November 21, 2024

Iterum Therapeutics Receives Delisting Determination Letter from Nasdaq Regarding its Failure to Meet the Terms of the Extension to Comply with the Minimum Stockholders’ Equity Requirement

New major risk - Shareholder dilution

Forecast to breakeven in 2026

Iterum Therapeutics plc to Report Q2, 2024 Results on Aug 14, 2024

New major risk - Shareholder dilution

Iterum Therapeutics plc Broadens Patent Estate for Oral Sulopenem

New major risk - Financial position

Iterum Therapeutics plc Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics plc Announces Executive Changes

Iterum Therapeutics plc to Report Q1, 2024 Results on May 13, 2024

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

Iterum Therapeutics plc, Annual General Meeting, Jun 19, 2024

Insufficient new directors

Iterum Therapeutics plc to Report Q4, 2023 Results on Mar 28, 2024

Iterum Therapeutics plc Announces Positive Topline Results from Its Phase 3 Reassure Clinical Trial of Oral Sulopenem in Un Complicated Urinary Tract Infections

New major risk - Financial position

Iterum Therapeutics plc Announces the Resignation of Mark Chin as Director, Effective December 31, 2023

New major risk - Revenue and earnings growth

Iterum Therapeutics plc to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Share price stability

Iterum Therapeutics plc Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

Iterum Therapeutics Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Iterum Therapeutics plc to Report Q2, 2023 Results on Aug 11, 2023

Iterum Therapeutics plc, Annual General Meeting, May 03, 2023

Iterum Therapeutics plc to Report Q3, 2022 Results on Nov 10, 2022

Iterum Announces First Patient Dosed in Reassure, A Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

Iterum Therapeutics plc Announces Issuance of Allowance for A U.S. Patent Covering Oral Sulopenem

Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.03

Iterum Therapeutics plc Announces Special Protocol Assessment Agreement with the FDA

Iterum jumps 64% as FDA agrees to Phase 3 trial for UTI candidate

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics plc, Annual General Meeting, Jun 15, 2022

Iterum Therapeutics plc to Report Q4, 2021 Results on Mar 28, 2022

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics Provides Update from FDA Type A Meeting Regarding Oral Sulopenem

Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?

Bernstein Liebhard Reminds Investors of the Deadline to File Lead Plaintiff Motion in Securities Class Action Lawsuit Filed Against Iterum Therapeutics plc

Pomerantz Law Firm Announces the Filing of Class Action against Iterum Therapeutics plc and Certain Officers

Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative Buy

Iterum Therapeutics plc Receives Letter from the U.S. Food and Drug Administration as Part of Their Ongoing Review of the New Drug Application for sulopenem etzadroxil/probenecid

Independent Director Mohammed Shahzad Malik has left the company

It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year

Consensus forecasts updated

Iterum Therapeutics plc Provides Update on NDA Review

Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?

Price target increased to US$2.00

Consensus revenue estimates increase to US$2.86m

Independent Director has left the company

Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors

Iterum Therapeutics plc to Report Q4, 2020 Results on Mar 12, 2021

New 90-day high: US$2.27

Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?

This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)

Iterum Therapeutics shares slide 13% on raising $10M

Iterum Therapeutics plc Announces Collaboration with Eversana to Support Oral Sulopenem Launch

President recently sold US$148k worth of stock

Iterum Therapeutics plc Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem

New 90-day high: US$1.23

Iterum Therapeutics plc Announces Executive Changes

Iterum Therapeutics rises 39% on RA Capital stake disclosure

Iterum Therapeutics files US application for sulopenem in urinary tract infections

Earnings beat expectations

Iterum Therapeutics EPS beats by $0.45